1. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series;Cain;Eur J Cancer,1974
2. Denny WA, Baguley BC, Cain BF, Waring MJ. Antitumour acridines. In: Neidle S, Waring MJ, eds. Molecular Aspects of Anticancer Drug Action. London, Macmillan, in press.
3. Phase I clinical investigation of 4′-(9-acridinylamino)methanesulfon-m-anisidide, (NSC 249992), a new acridine derivative;Legha;Cancer Res,1978
4. Phase II study of 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma;Tan;Cancer Res,1982
5. Phase II study of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer;Legha;Cancer Treat Rep,1979